Cibinetide

What is Cibinetide?

A tissue-protective peptide studied for neuropathy and inflammation with promising but limited clinical results.

This profile is educational. It organizes publicly discussed research context for Cibinetide and related naming aliases — it is not a treatment guide.

Proposed mechanism

Activates innate repair receptor (IRR), a heteromer of EPO receptor and CD131, promoting anti-inflammatory and cytoprotective signaling without erythropoietic effects.

Mechanism language on PepGuide describes how researchers discuss pathways. Proposed mechanisms can change as evidence evolves.

Current research notes

Human evidence grade: Limited human evidence

Preclinical evidence grade: Moderate human evidence

ARA-290 (cibinetide) was studied in sarcoidosis-associated neuropathy and diabetic neuropathy with mixed phase 2 results. Researchers highlight non-hematopoietic EPO pathway activation. Human evidence is limited to specific neuropathy contexts; not FDA approved.

Key uncertainties

• Regulatory path forward
• Efficacy in broader neuropathies

Research areas being studied

• Neuropathic pain
• Sarcoidosis neuropathy
• Tissue protection

Being studied for a topic is not the same as proven benefit in that topic. Prefer primary literature for study design, endpoints, and limitations.

Safety & side-effect notes

Reported or discussed adverse effects

• Generally well tolerated in trials
• Injection-site reactions

Additional risks & considerations

• Development setbacks in some indications
• Limited generalizability

Regulatory status

Investigational

Regulatory framing here is educational and can lag policy changes. Check official sources for current status.

Frequently asked questions

References & sources

• Dahan A et al. (2013). ARA 290 for sarcoidosis-associated neuropathy — Mol Med. Evidence type: human.